By changing their surroundings and lifestyle, travelers with allergic conditions exposed themselves to new risks. The main perennial allergens are house dust mites which thrive in tropical areas and can be especially sensitizing. The risk of seasonal reactions to grass-pollens varies from region to region. Reactions to some highly sensitizing respiratory allergens can occur in travelers who return to regions where they were previously exposed. Subjects with food allergies should beware of possible reactions to ingredients in exotic dishes. The bites of several insects can cause anaphylactic reactions. Some medications required for tropical travel (e.g. antimalarial drugs) can trigger severe hypersensitivity reactions. Avoidance of allergens is more difficult during travel. Travelers with allergic conditions should carry alert identification cards and medications for routine as well as emergency treatment including self-injectable adrenaline.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Chronic urticaria treatment challenges in children.
Rev Paul Pediatr
January 2025
Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Objective: This paper aims to review the efficacy and safety of current chronic urticaria (CU) treatment in children and the existing patient-reported outcome measures (PROMs) used in this age group.
Data Source: Since there are few studies of CU in children, the authors performed a non-systematic review of published articles in English, Spanish, and Portuguese in the PubMed database in the last decade. Keywords used were (antihistamines OR omalizumab OR cyclosporine OR treatment) AND (chronic urticaria) AND (children OR adolescents).
Editorial: Animal models of allergic diseases: from basic to preclinical research.
Front Allergy
December 2024
Deptartment of Dermatology, University of Zurich & University Hospital Zurich, Zurich, Switzerland.
The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study.
Travel Med Infect Dis
January 2025
State Key Laboratory of Antibody Research &Development, Hebei Engineering Research Center of Antibody Medicine, North China Pharmaceutical Company New Drug Research and Development Co., Ltd., Shijiazhuang, 050015, China. Electronic address:
Background: The combination of passive immune agents (human rabies immune globulin (HRIG) and equine rabies antiserum (ERA)) with vaccines are effective measures for preventing the onset of rabies post exposure. However, ERA and HRIG have potential risks of serum allergic reactions and blood-transmitted infectious diseases. This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone.
View Article and Find Full Text PDFActionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).
J Thorac Oncol
December 2024
Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano, Turin, Italy. Electronic address:
Introduction: The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients' access to clinical trials in Europe.
Methods: From January 2021 to December 2023, 20 centers located at five different European countries (Greece, Slovenia, Romania, Albania, and Italy) joined EPROPA, with 555 patients with advanced NSCLC registered to the program. Anonymized patients' clinical-pathological data were shared through the EPROPA web platform and tissue samples were collected at the Molecular Pathology Unit of the Reference Center (University of Turin) for molecular analyses.
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial.
Lancet Reg Health Eur
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
Article Synopsis
- The study focuses on the effectiveness of a sublingual immunotherapy (SLIT) tablet for treating house dust mite-induced allergic rhinitis in children aged 5-11 years, addressing a gap in existing data for this age group.
- Conducted as a Phase III randomized trial, 1460 children were divided into two groups: one receiving the SLIT tablet and the other receiving a placebo, with significant improvements observed in allergy symptoms and quality of life for the SLIT group.
- Results showed a notable 22% reduction in the total combined rhinitis score for the SLIT group compared to placebo, alongside improved scores in other related outcome measures, suggesting SLIT's potential as an effective
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!